Relief Therapeutics Holding AG (RLFTF)

[rollup]

NRX on LinkedIN
NIH ACTIV3b TESICO Trial
Preliminary DSMB results just in

348 patients randomized at steady rate of enrollment
Congratulations on accrual and study conduct.
Thanks for thorough open and closed reports
No new substantive safety concerns.
Continue as planned
Frequency of emailed safety summaries can be more than every 2 weeks if accruals are < 20
Next meeting in about 6 weeks at end of January
Formal report expected shortly.